col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

39 Results       Page 1

Elsevier: Therapies
  original article Date Title Authors   All Authors
1 [GO] 2022―May―07 Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic Émilien Schultz, Léo Mignot, Jeremy Ward, Daniela Boaventura, Christian Chabannon, Julien Mancini
2 [GO] 2022―Apr―27 Adverse drug reactions and ivermectin in COVID-19 Jean-Louis Montastruc
3 [GO] 2022―Apr―26 Cluster headache after COVID-19 vaccination with Comirnaty: a signal in pharmacovigilance database* Michaël Rochoy, Eric Billy, Franck Clarot, Victor Dumortier, Sophie Gautier, Romain Barus
4 [GO] 2022―Apr―20 Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO’s pharmacovigilance database Jeremy T. Campillo, Jean-Luc Faillie
5 [GO] 2022―Apr―20 Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard, et al. (+12)
6 [GO] 2021―Dec―28 Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic Pauline Lory, Jeffrey Lombardi, Clémence Lacroix, Paola Sanchez-Pena, Serena Romani, Aurélie Grandvuillemin
7 [GO] 2021―Dec―04 Lessons from the COVID-19 pandemic Philippe Lechat
8 [GO] 2021―Oct―25 A historical cohort stuy to investigation of statins safety in COVID-19 hospitalized patients Saeed Nateghi, Mohammad Mahmoudi Gomari, Hadiseh Hosamirudsari, Behnam Behnoush, Asma Razmjoofard, Goli Azimi, et al. (+3)
9 [GO] 2021―Oct―08 Peptides-based therapeutics: emerging potential therapeutic agents for COVID-19 Jagat Narayan Shah, Guang-Qin Guo, Anand Krishnan, Muthusamy Ramesh, Naresh Kumar Katari, Mohd Shahbaaz, et al. (+3)
10 [GO] 2021―Jul―27 Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against SARS-CoV-2 and the urgent need of a large immunization in healthcare workers Laurent Chouchana, Etienne Canouï, Rui Batista, Adrien Contejean, Alain Cariou, Jean Marc Treluyer, Caroline Charlier
11 [GO] 2021―Jun―01 COVID-19 vaccines and pregnancy: what do we know? Judith Cottin, Justine Benevent, Sophie Khettar, Isabelle Lacroix
12 [GO] 2021―May―28 COVID-19 vaccines: a perspective from social pharmacology Jean-Louis Montastruc, Margaux Lafaurie, Claire de Canecaude, François Montastruc, Haleh Bagheri, Geneviève Durrieu, Agnès Sommet
13 [GO] 2021―May―28 COVID-19: Pharmacology has kept the science ship running during the storm Mathieu Molimard, Vincent Richard, Jean-Luc Cracowski
14 [GO] 2021―May―12 Efficacy of Covid-19 vaccines: from clinical trials to real life Dominique Deplanque, Odile Launay
15 [GO] 2021―May―07 French organization for the Pharmacovigilance of COVID-19 vaccines: a major challenge Clémence Lacroix, Francesco Salvo, Valérie Gras-Champel, Sophie Gautier, Nathalie Massy, Marie-Blanche Valnet-Rabier, et al. (+6)
16 [GO] 2021―May―07 Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects Antoine Pariente, Julien Bezin
17 [GO] 2021―Apr―29 Eruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19* Nihal Bekkali, Tanguy Allard, Eric Estève, Céline Lengellé
18 [GO] 2021―Apr―02 Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy Thomas Soeiro, Francesco Salvo, Antoine Pariente, Aurélie Grandvuillemin, Annie-Pierre Jonville-Béra, Joëlle Micallef
19 [GO] 2021―Mar―06 Pneumopathie médicamenteuse ou liée à la COVID-19: un train peut en cacher un autre! Mélanie Vasseur, Marine Tambon, Mireille Gony, Nicolas Lebrun, Haleh Bagheri
20 [GO] 2021―Feb―16 Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19 Zineb Ghrieb, Souhil Allaoua, Jin Huang, Nathalie Langner, Florène François, Corinne Maréchal, et al. (+8)
21 [GO] 2021―Jan―28 Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19 Noël Zahr, Saik Urien, Benoit Llopis, Valérie Pourcher, Olivier Paccoud, Alexandre Bleibtreu, et al. (+11)
22 [GO] 2021―Jan―20 Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center Mathieu Chappuy, Marie Peyrat, Olivier Lejeune, Nathalie Duvernay, Brigitte David, Philippe Joubert, Philippe Lack
23 [GO] 2021―Jan―19 DPP-4 inhibitors and severe course of illness in patients with COVID-19 Béatrice Bouhanick, Jean-Luc Cracowski, Jean-Luc Faillie
24 [GO] 2020―Dec―26 A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19 Chia Siang Kow, Syed Shahzad Hasan
25 [GO] 2020―Nov―01 Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? Shivshankar Malkarjun Gunjegaonkar, Thukani Sathanantham Shanmugarajan, Mohanasundaram Arunsundar, Uppuluri Varuna Naga Venkata Arjun, Kadirrel Devi, Sagar Baliram Wankhede, Velayutham Ravichandiran
26 [GO] 2020―Oct―17 Modifications pharmacocinétiques liées à une infection aigue. Exemples issus de la pandémie de SARS-Cov2 Anaëlle Chavant, Elodie Gautier-Veyret, Stéphanie Chhun, Romain Guilhaumou, Françoise Stanke-Labesque
27 [GO] 2020―Jul―22 COVID-19 and NSAIDs: Primum non nocere Joëlle Micallef, Thomas Soeiro, Annie-Pierre Jonville Béra
28 [GO] 2020―Jul―12 No arguments for extra risk from ibuprofen in SARS-COV2 infection Nicholas Moore
29 [GO] 2020―Jun―27 NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection Medine Cumhur Cure, Adem Kucuk, Erkan Cure
30 [GO] 2020―Jun―27 Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: a review Lucile Grange, Philippe Guilpain, Marie-Elise Truchetet, Jean-Luc Cracowski
31 [GO] 2020―Jun―23 Addictovigilance contribution during COVID-19 epidemic and lockdown in France Maryse Lapeyre-Mestre, Alexandra Boucher, Amelie Daveluy, Valerie Gibaja, Emilie Jouanjus, Michel Mallaret, et al. (+2)
32 [GO] 2020―Jun―06 Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard
33 [GO] 2020―May―23 Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence Matthieu Roustit, Romain Guilhaumou, Mathieu Molimard, Milou Drici, Silvy Laporte, Jean-Louis Montastruc
34 [GO] 2020―May―20 Renin-angiotensin-aldosterone system and COVID-19 infection Joachim Alexandre, Jean-Luc Cracowski, Vincent Richard, Béatrice Bouhanick
35 [GO] 2020―May―15 Diabetes and COVID-19 Béatrice Bouhanick, Jean Luc Cracowski, Jean Luc Faillie
36 [GO] 2020―May―15 Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France François Montastruc, Charles Romano, Jean-Louis Montastruc, Stein Silva, Thierry Seguin, Vincent Minville, et al. (+3)
37 [GO] 2020―May―07 Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection Joëlle Micallef, Thomas Soeiro, Jonville-Béra Annie-Pierre
38 [GO] 2020―May―07 “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Alexandre Gérard, Serena Romani, Audrey Fresse, Delphine Viard, Nadège Parassol, Aurélie Granvuillemin, et al. (+3)
39 [GO] 2020―May―05 Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data Aurélie Grandvuillemin, Audrey Fresse, Clément Cholle, Samir Yamani, Anne Dautriche

39 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.022 sec